Evidence map›Paper›PMID 25387827›Full record

ArticleG3 (Bethesda, Md.)2014

Expression of MTAP inhibits tumor-related phenotypes in HT1080 cells via a mechanism unrelated to its enzymatic function.

Baiqing Tang, Yuwaraj Kadariya, Yibai Chen, Michael Slifker, Warren D Kruger

Open access · goldAbstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Current issues in molecular biology · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Baiqing TangCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Yuwaraj KadariyaCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Yibai ChenCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Michael SlifkerBiostatistics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Warren D KrugerCancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 warren.kruger@fccc.edu.
Fox Chase Cancer Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
The Role of Methylthioadenosine Phosphorylase Loss in TumorigenesisR01CA131024 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI KRUGER, WARREN D · 2009 to 2013
$1.8M
NCI NIH HHS CA06927NCI NIH HHS CA131024NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA131024
6 · The paper itself

Abstract

Methylthioadenosine Phosphorylase (MTAP) is a tumor suppressor gene that is frequently deleted in human cancers and encodes an enzyme responsible for the catabolism of the polyamine byproduct 5'deoxy-5'-methylthioadenosine (MTA). To elucidate the mechanism by which MTAP inhibits tumor formation, we have reintroduced MTAP into MTAP-deleted HT1080 fibrosarcoma cells. Expression of MTAP resulted in a variety of phenotypes, including decreased colony formation in soft-agar, decreased migration, decreased in vitro invasion, increased matrix metalloproteinase production, and reduced ability to form tumors in severe combined immunodeficiency mice. Microarray analysis showed that MTAP affected the expression of genes involved in a variety of processes, including cell adhesion, extracellular matrix interaction, and cell signaling. Treatment of MTAP-expressing cells with a potent inhibitor of MTAP's enzymatic activity (MT-DADMe-ImmA) did not result in a MTAP- phenotype. This finding suggests that MTAP's tumor suppressor function is not the same as its known enzymatic function. To confirm this, we introduced a catalytically inactive version of MTAP, D220A, into HT1080 cells and found that this mutant was fully capable of reversing the soft agar colony formation, migration, and matrix metalloproteinase phenotypes. Our results show that MTAP affects cellular phenotypes in HT1080 cells in a manner that is independent of its known enzymatic activity.

Indexed as

AnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMice, SCIDNeoplasmsOligonucleotide Array Sequence AnalysisOrnithine DecarboxylasePhenotypePolyaminesPurine-Nucleoside PhosphorylaseReal-Time Polymerase Chain ReactionTumor BurdenWound Healing5'-methylthioadenosine phosphorylaseOrnithine DecarboxylasePolyaminesPurine-Nucleoside Phosphorylasecell mobility and migrationmethioninesuppressor genes

Identifiers

PMID25387827
PMCPMC4291467
OpenAlexW2327635600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.